New Standard of Care in SMA is published

A new Standard of Care in spinal muscular atrophy has been published.

Eight years after the original Consensus Statement for Standard of Care in Spinal Muscular Atrophy was first published in 2007, doctors from all over the world realised that it was time to update the Standard with new experience and knowledge. Soon, eight teams, each composed of eight experts, began huge collabroative work on a new document that would set a new standard of care in spinal muscular atrophy.

Several meetings, thousands of discussions and three years later the outcome was published in the respected medical journal Neuromuscular Disorders. The publication, in two parts, carries a simple title: “Diagnosis and management of spinal muscular atrophy”.

While a work in progress in a few places, the Standard is a major upgrade over what was available before. Below, we are sharing the publications for the benefit of both SMA families and healthcare professionals.

PART 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care

Download Standard of Care Part 1

PART 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics

Download Standard of Care Part 2

We wish these medical guidelines are accepted and followed by all the doctors who care for patients with spinal muscular atrophy.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more